Choose your language:
EnglishEN中文 | عربيZH
Facebook
LinkedIn

IHD

Project IHD

Introduction

Project IHD is an Australian unlisted public company founded in 2004 to develop biopharmaceutical drugs in the immunology space as follows:

  • Key indications being treated are heart failure and cardiomyopathy (resulting from cardiac inflammation and fibrosis).
  • Developed a drug candidate that regulates inflammatory responses to infection and injury (inflammatory heart diseases).
  • Commercialising drug platform via Phase 1b patient trials underway in the USA (clinical studies).
  • Strong IP platform including patents and orphan drug designation.
  • Project IHD founders have extensive research and commercialization experience.
  • Plan to exit via trade sale.

BEFORE DOWNLOADING, PRINTING OR VIEWING THE PROJECT IHD DOCUMENT, YOU MUST CAREFULLY READ THE TERMS SET OUT IN THIS NOTICE.

BlueMount Capital (QLD) Pty Ltd ACN 147 942 603 (BlueMount), provides capital raising services.

We wish to advise that:

  1. BlueMount will receive an agreed fee for providing the capital raising service;
  2.  Neither this Publication nor BlueMount are endorsed or approved by ASIC;
  3. Investment in new business carries high risks. It is highly speculative and before investing in any project about which information is given, prospective investors are strongly advised to take appropriate professional advice before accepting an offer for issue or sale of any securities or scheme interests;
  4. The information contained in this Publication has been prepared by or on behalf of the person who is proposing to issue or sell the securities or scheme interests (Issuer) and neither BlueMount, its officers, employees and agents have undertaken an independent review of the information contained in the Publication;
  5. The information contained in this Publication about any proposed business opportunity and the securities or scheme interests is not intended to be the only information on which the investment decision is made and is not a substitute for a disclosure document, Product Disclosure Statement or any other notice that may be required under the Act, as the Act may apply to the investment. Detailed information may be needed to make an investment decision, for example: financial statements; a business plan; information about ownership of intellectual or industrial property; or expert opinions including valuations or auditors’ reports;
  6. Prospective investors should be aware that no established market exists for the trading of any securities or scheme interests that may be offered;
  7. No information provided in this publication is to be construed as a solicitation to make any financial investment. It is provided for information purposes only;
  8. BlueMount does not provide financial advice and does not guarantee the performance of any securities or scheme interests.
  9. Prospective Investors warrant that they are not any of the following: A “U.S. PERSON” AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT, (B) A PERSON ACTING ON BEHALF OF ANY “U.S. PERSON” OR A PERSON IN THE UNITED STATES, NOR (C) A PERSON WHO IS LOCATED IN THE UNITED STATES. “U.S. PERSON” MEANS A U.S. PERSON AS DEFINED IN REGULATION S (THE DEFINITION OF WHICH INCLUDES, BUT IS NOT LIMITED TO, (I) ANY NATURAL PERSON RESIDENT IN THE UNITED STATES, (II) ANY PARTNERSHIP OR CORPORATION ORGANIZED OR INCORPORATED UNDER THE LAWS OF THE UNITED STATES, (III) ANY PARTNERSHIP OR CORPORATION ORGANIZED OUTSIDE OF THE UNITED STATES BY A U.S. PERSON PRINCIPALLY FOR THE PURPOSE OF INVESTING IN SECURITIES NOT REGISTERED UNDER THE U.S. SECURITIES ACT, UNLESS IT IS ORGANIZED, OR INCORPORATED, AND OWNED, BY ACCREDITED INVESTORS WHO ARE NOT NATURAL PERSONS, ESTATES OR TRUSTS, AND (IV) ANY ESTATE OR TRUST OF WHICH ANY EXECUTOR OR ADMINISTRATOR OR TRUSTEE IS A U.S. PERSON)

EXCLUDED OFFER
Any offer of securities in the Company contained in this document is an offer of securities which does not require disclosure to investors under Part 6D.2 Section 708 of the Corporations Act 2001 (Cth), and is therefore only open to Sophisticated Investors, Professional Investors and other investors to whom an offer can be made under Part 6D.2 of the Act without the need for a disclosure document. The closing date for this offer is 30 September 2024.

DISCLOSURE
BlueMount Capital (Qld) Pty Ltd is authorised under AFS Licence Number 230680, Corporate Authorised Representative number 398161. BlueMount Capital (Qld) Pty Ltd, its directors and associates may earn corporate advisory or capital raising fees from Project IHD, including options or shares in the Company which are not yet included in this document.

JURISDICTIONAL DISCLAIMER

No action has been taken to register or qualify the securities of companies published in this publication or our website or otherwise to permit a public offering of the securities on offer in any jurisdiction outside Australia. Further, this publication and our website (www.bluemountcapital.com) do not constitute an offer to sell, a solicitation of, or an invitation to subscribe for or to buy, securities in the United States or in relation to any U.S. person (as defined in Regulation S under the U.S. Securities Act of 1933, as amended (“the U.S. Securities Act”)).

ACKNOWLEDGEMENTS

By Registering on this website I acknowledge that I have read and understood the above information including investor warnings and statements, and I wish to receive information from BlueMount and/or the Issuer from time-to- time.

By proceeding, you confirm you are a resident of Australia, accessing this website from within Australia.

Download Now!